JP2023544716A5 - - Google Patents
Info
- Publication number
- JP2023544716A5 JP2023544716A5 JP2023519608A JP2023519608A JP2023544716A5 JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5 JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5
- Authority
- JP
- Japan
- Prior art keywords
- methylpyridine
- pyrazole
- acetamide
- quinoline
- benzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382861.1 | 2020-09-30 | ||
| EP20382861.1A EP3978487A1 (en) | 2020-09-30 | 2020-09-30 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| PCT/EP2021/076730 WO2022069509A1 (en) | 2020-09-30 | 2021-09-29 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544716A JP2023544716A (ja) | 2023-10-25 |
| JP2023544716A5 true JP2023544716A5 (https=) | 2024-10-08 |
| JP7752684B2 JP7752684B2 (ja) | 2025-10-10 |
Family
ID=72744716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519608A Active JP7752684B2 (ja) | 2020-09-30 | 2021-09-29 | トランスフォーミング増殖因子－β受容体Ｉ／ＡＬＫ５の阻害剤としての２－（３－ピリジン－２－イル－４－キノリン－４－イル－ピラゾール－１－イル）－アセタミド誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12577230B2 (https=) |
| EP (2) | EP3978487A1 (https=) |
| JP (1) | JP7752684B2 (https=) |
| KR (1) | KR20230079027A (https=) |
| CN (1) | CN116323601A (https=) |
| AR (1) | AR123543A1 (https=) |
| AU (1) | AU2021353965A1 (https=) |
| BR (1) | BR112023004612A2 (https=) |
| CA (1) | CA3196108A1 (https=) |
| ES (1) | ES3029607T1 (https=) |
| IL (1) | IL301663B1 (https=) |
| MX (1) | MX2023002900A (https=) |
| PH (1) | PH12023550777A1 (https=) |
| WO (1) | WO2022069509A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| WO2026017797A1 (en) | 2024-07-17 | 2026-01-22 | Agomab Spain S.L.U. | Crystalline forms |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU754830C (en) * | 1997-05-22 | 2004-02-12 | G.D. Searle Llc | Substituted pyrazoles as p38 kinase inhibitors |
| ATE291020T1 (de) * | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| WO2007005951A2 (en) * | 2005-07-05 | 2007-01-11 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| US20210002265A1 (en) | 2018-03-02 | 2021-01-07 | Université de Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-09-30 EP EP20382861.1A patent/EP3978487A1/en not_active Withdrawn
-
2021
- 2021-09-17 AR ARP210102591A patent/AR123543A1/es unknown
- 2021-09-29 BR BR112023004612A patent/BR112023004612A2/pt unknown
- 2021-09-29 PH PH1/2023/550777A patent/PH12023550777A1/en unknown
- 2021-09-29 ES ES21786169T patent/ES3029607T1/es active Pending
- 2021-09-29 CN CN202180066883.4A patent/CN116323601A/zh active Pending
- 2021-09-29 MX MX2023002900A patent/MX2023002900A/es unknown
- 2021-09-29 IL IL301663A patent/IL301663B1/en unknown
- 2021-09-29 WO PCT/EP2021/076730 patent/WO2022069509A1/en not_active Ceased
- 2021-09-29 CA CA3196108A patent/CA3196108A1/en active Pending
- 2021-09-29 AU AU2021353965A patent/AU2021353965A1/en active Pending
- 2021-09-29 KR KR1020237008242A patent/KR20230079027A/ko active Pending
- 2021-09-29 EP EP21786169.9A patent/EP4222149B1/en active Active
- 2021-09-29 US US18/246,903 patent/US12577230B2/en active Active
- 2021-09-29 JP JP2023519608A patent/JP7752684B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544716A5 (https=) | ||
| CA3093851A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| JP2019517487A5 (https=) | ||
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| JP2017502033A5 (https=) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2022505841A5 (https=) | ||
| JP2005538099A5 (https=) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| CN107325048A (zh) | 使用c‑Met调节剂的方法 | |
| ES3029607T1 (en) | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2008509187A5 (https=) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2020527173A5 (https=) | ||
| JP2007505931A5 (https=) | ||
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2013542267A5 (https=) | ||
| JP2024510939A5 (https=) | ||
| CA3178372A1 (en) | Enpp1 modulators and uses thereof | |
| PT1948176E (pt) | Diaril ureias para tratar a hipertensão pulmonar | |
| WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists |